Pioneering treatments for neurodegenerative diseases
BioArctic (bioarctic.com) scores 76 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 53rd percentile of 20342 Healthcare brands.
BioArctic AB is a Swedish research-based biopharmaceutical company founded in 2003 and headquartered in Stockholm Municipality. It focuses on developing disease-modifying treatments for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS. The company is known for its antibody therapy lecanemab, developed to target underlying disease mechanisms rather than just symptoms. BioArctic collaborates with healthcare providers, researchers, and pharmaceutical partners to advance its research and development programs in this therapeutic area.
| Brand Name | BioArctic |
|---|---|
| Domain | bioarctic.com |
| Industry | Healthcare |
| Founded | 2003 |
| Headquarters | Stockholm Municipality |
| Main Competitors | Eli Lilly (78/100), Roche (81/100), Biogen (78/100), AC Immune (79/100), Prothena (82/100), Denali Therapeutics (77/100), Alector (79/100) |
Moz Domain Authority 35/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s …" (Meta description: 24 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt mentions GPTBot, ClaudeBot, Google-Extended, PerplexityBot - all allowed - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, Instagram, GitHub; no detected presence on Facebook, X (Twitter), YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is BioArctic?", Claude could identify the brand as of October 2026. BioArctic is a Swedish biopharmaceutical company focused on developing treatments for neurodegenerative diseases, most notably Alzheimer's disease. It co-developed lecanemab (brand name Leqembi) with Eisai, one of the first amyloid-targeting antibodies to receive regulatory appro Best known for Co-developing lecanemab (Leqembi), an approved amyloid-beta targeting antibody therapy for Alzheimer's disease.
When asked "Best brands similar to BioArctic?", Claude would recommend BioArctic as of October 2026. BioArctic is a notable name in Alzheimer's drug development due to its partnership on Leqembi, making it relevant if discussing leading biotech companies in neurodegenerative disease research.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
BioArctic's main competitors in Healthcare: Eli Lilly (78/100), Roche (81/100), Biogen (78/100), AC Immune (79/100), Prothena (82/100).
Sources: Brand Analyzer scan
BioArctic develops disease-modifying treatments for neurodegenerative diseases, with its antibody therapy lecanemab cited as a key example of its product development targeting Alzheimer's disease, Parkinson's disease, and ALS.
Sources: BioArctic official site
BioArctic AB is a Swedish research-based biopharmaceutical company founded in 2003 and headquartered in Stockholm Municipality. It specializes in developing disease-modifying treatments for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS.
Sources: BioArctic official site
BioArctic has limited AI-search visibility, scoring 25/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 12, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: BioArctic official site
BioArctic was founded in 2003. BioArctic operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
BioArctic is headquartered in Stockholm Municipality. BioArctic operates in the Healthcare category.
Sources: Wikidata
BioArctic conducts research and development of disease-modifying treatments that target the underlying causes of neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. A notable example of its work is the antibody therapy lecanemab, developed to address the biological mechanisms driving these conditions rather than only alleviating symptoms.
Sources: BioArctic official site
BioArctic scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: BioArctic official site
BioArctic is known for its research into disease-modifying treatments for neurodegenerative diseases, most notably for developing the antibody therapy lecanemab aimed at Alzheimer's disease.
Sources: BioArctic official site
BioArctic can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: BioArctic official site
BioArctic's target audience includes patients suffering from neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS, as well as healthcare providers, researchers, and pharmaceutical partners who engage with its research and treatments.
Sources: BioArctic official site
BioArctic scores 25/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
BioArctic has a weak AI-visibility profile at 25/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is trust (12/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 35/100 and thin schema.org structured data. In a live check, Claude could already identify BioArctic from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to BioArctic: BillionToOne (76/100), Behavioral Health Network Inc. (BHN) (76/100), Biochemical Society (76/100), Biolin Scientific (76/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.